| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A perivascular niche for brain tumor stem cells.
|
Cancer Cell
|
2007
|
11.55
|
|
2
|
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
|
Nat Genet
|
2012
|
7.61
|
|
3
|
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
|
Lancet Oncol
|
2006
|
6.92
|
|
4
|
Molecular subgroups of medulloblastoma: the current consensus.
|
Acta Neuropathol
|
2011
|
6.67
|
|
5
|
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
|
J Clin Oncol
|
2006
|
5.96
|
|
6
|
Subtypes of medulloblastoma have distinct developmental origins.
|
Nature
|
2010
|
5.94
|
|
7
|
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation.
|
Nature
|
2008
|
5.59
|
|
8
|
Radial glia cells are candidate stem cells of ependymoma.
|
Cancer Cell
|
2005
|
5.21
|
|
9
|
Novel mutations target distinct subgroups of medulloblastoma.
|
Nature
|
2012
|
4.82
|
|
10
|
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
Nat Genet
|
2009
|
4.52
|
|
11
|
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
|
J Clin Oncol
|
2010
|
4.48
|
|
12
|
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
|
Acta Neuropathol
|
2012
|
3.88
|
|
13
|
Cross-species genomics matches driver mutations and cell compartments to model ependymoma.
|
Nature
|
2010
|
3.70
|
|
14
|
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
|
Nat Genet
|
2013
|
3.51
|
|
15
|
Medulloblastomics: the end of the beginning.
|
Nat Rev Cancer
|
2012
|
3.01
|
|
16
|
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
|
Acta Neuropathol
|
2011
|
2.82
|
|
17
|
Dual and opposing roles of primary cilia in medulloblastoma development.
|
Nat Med
|
2009
|
2.73
|
|
18
|
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.
|
Proc Natl Acad Sci U S A
|
2009
|
2.72
|
|
19
|
A molecular fingerprint for medulloblastoma.
|
Cancer Res
|
2003
|
2.66
|
|
20
|
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
|
Cell Cycle
|
2006
|
2.37
|
|
21
|
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
|
J Clin Oncol
|
2005
|
2.19
|
|
22
|
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
|
J Clin Oncol
|
2004
|
2.16
|
|
23
|
A mouse model of the most aggressive subgroup of human medulloblastoma.
|
Cancer Cell
|
2012
|
2.15
|
|
24
|
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation.
|
Genes Dev
|
2005
|
2.14
|
|
25
|
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.
|
J Neurosci Res
|
2008
|
1.96
|
|
26
|
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
|
Cancer Cell
|
2011
|
1.78
|
|
27
|
Clinical and molecular characteristics of malignant transformation of low-grade glioma in children.
|
J Clin Oncol
|
2007
|
1.67
|
|
28
|
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
|
Clin Cancer Res
|
2007
|
1.61
|
|
29
|
Phase I study of everolimus in pediatric patients with refractory solid tumors.
|
J Clin Oncol
|
2007
|
1.61
|
|
30
|
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
|
Cancer Res
|
2007
|
1.58
|
|
31
|
Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors.
|
Cancer Res
|
2007
|
1.51
|
|
32
|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Neurooncol
|
2013
|
1.51
|
|
33
|
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.50
|
|
34
|
PDGFRB is overexpressed in metastatic medulloblastoma.
|
Nat Genet
|
2003
|
1.46
|
|
35
|
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop.
|
J Neurosurg Spine
|
2010
|
1.45
|
|
36
|
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
|
J Clin Oncol
|
2010
|
1.42
|
|
37
|
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.
|
Cancer Res
|
2003
|
1.41
|
|
38
|
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Clin Oncol
|
2011
|
1.39
|
|
39
|
Rapid diagnosis of medulloblastoma molecular subgroups.
|
Clin Cancer Res
|
2011
|
1.33
|
|
40
|
Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
|
Neuro Oncol
|
2008
|
1.33
|
|
41
|
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
|
J Clin Oncol
|
2010
|
1.27
|
|
42
|
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
|
Clin Cancer Res
|
2013
|
1.20
|
|
43
|
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
|
J Clin Oncol
|
2011
|
1.18
|
|
44
|
The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma.
|
Brain Res Mol Brain Res
|
2004
|
1.17
|
|
45
|
What's new in neuro-oncology? Recent advances in medulloblastoma.
|
Eur J Paediatr Neurol
|
2003
|
1.16
|
|
46
|
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
|
J Clin Oncol
|
2008
|
1.13
|
|
47
|
Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
|
Carcinogenesis
|
2003
|
1.13
|
|
48
|
WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum.
|
Development
|
2012
|
1.12
|
|
49
|
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.10
|
|
50
|
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
|
Eur J Cancer
|
2010
|
1.09
|
|
51
|
Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature.
|
Mol Cancer Res
|
2007
|
1.07
|
|
52
|
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2.
|
Neuro Oncol
|
2008
|
1.07
|
|
53
|
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
|
Acta Neuropathol
|
2011
|
1.04
|
|
54
|
The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy.
|
J Neurosci
|
2013
|
1.03
|
|
55
|
Cancer: Resolving the stem-cell debate.
|
Nature
|
2012
|
1.01
|
|
56
|
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours.
|
Int J Cancer
|
2006
|
1.00
|
|
57
|
Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
|
Clin Cancer Res
|
2012
|
0.99
|
|
58
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
|
59
|
Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.
|
Neuro Oncol
|
2008
|
0.96
|
|
60
|
TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas.
|
J Clin Oncol
|
2011
|
0.96
|
|
61
|
Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects.
|
Development
|
2012
|
0.95
|
|
62
|
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2012
|
0.92
|
|
63
|
Molecular profiling of pediatric brain tumors: insight into biology and treatment.
|
Curr Oncol Rep
|
2009
|
0.87
|
|
64
|
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
|
Pediatr Blood Cancer
|
2013
|
0.87
|
|
65
|
There's a time and a place for MYCN.
|
Cancer Cell
|
2012
|
0.84
|
|
66
|
The niche revealed.
|
Cell Stem Cell
|
2008
|
0.84
|
|
67
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
|
68
|
A procedure to statistically evaluate agreement of differential expression for cross-species genomics.
|
Bioinformatics
|
2011
|
0.82
|
|
69
|
Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.
|
Cancer Res
|
2008
|
0.82
|
|
70
|
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.
|
Cancer Chemother Pharmacol
|
2015
|
0.81
|
|
71
|
Finding the perfect partner for medulloblastoma prognostication.
|
J Clin Oncol
|
2011
|
0.78
|
|
72
|
To infinium, and beyond!
|
Cancer Cell
|
2010
|
0.76
|
|
73
|
Developing treatment strategies for rare cancers.
|
Oncotarget
|
2011
|
0.75
|
|
74
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
75
|
896 Anatomic Variants of Ependymoma Arise from Distinct Subsets of Radial Glial Cells.
|
Neurosurgery
|
2005
|
0.75
|